Review

Genetics of Parkinson's disease: An introspection of its journey towards precision medicine

Sara Bandres-Ciga[a,b,*,1], Monica Diez-Fairen[a,c,1], Jonggeol Jeff Kim[a,1], Andrew B. Singleton[a,1]

[a] Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA
[b] Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada 18016, Spain
[c] Fundació Docència i Recerca Mútua Terrassa and Movement Disorders Unit, Department of Neurology, University Hospital Mútua Terrassa, Terrassa 08221, Barcelona, Spain

ABSTRACT

A substantial proportion of risk for Parkinson's disease (PD) is driven by genetics. Progress in understanding the genetic basis of PD has been significant. So far, highly-penetrant rare genetic alterations in *SNCA, LRRK2, VPS35, PRKN, PINK1, DJ-1* and *GBA* have been linked with typical familial PD and common genetic variability at 90 loci have been linked to risk for PD. In this review, we outline the journey thus far of PD genetics, highlighting how significant advances have improved our knowledge of the genetic basis of PD risk, onset and progression. Despite remarkable progress, our field has yet to unravel how genetic risk variants disrupt biological pathways and molecular networks underlying the pathobiology of the disease. We highlight that currently identified genetic risk factors only represent a fraction of the likely genetic risk for PD. Identifying the remaining genetic risk will require us to diversify our efforts, performing genetic studies across different ancestral groups. This work will inform us on the varied genetic basis of disease across populations and also aid in fine mapping discovered loci. If we are able to take this course, we foresee that genetic discoveries in PD will directly influence our ability to predict disease and aid in defining etiological subtypes, critical steps for the implementation of precision medicine for PD.

1. Introduction

Parkinson's disease (PD) is a neurodegenerative disease characterized by the presence of Lewy bodies in the midbrain and the loss of activity of dopaminergic neurons, particularly in the substantia nigra. First clinically described by James Parkinson in 1817, PD exhibits symptoms that include muscle tremors and rigidity, bradykinesia and loss of balance, among others (Poewe et al., 2017). Years before distinct neuromotor symptoms are manifest, PD initially begins in a long prodromal period. Patients with prodromal PD present non-motor symptoms such as constipation and REM sleep disorder (Heinzel et al., 2019). PD currently has no cure and treatments are only symptomatic.

PD exerts a significant burden on the global economy and society, and this is expected to worsen; as of 2016, there are estimated to be more than 6 million PD cases. As the fastest growing neurological disorder in disability-adjusted life years, deaths, and prevalence (GBD 2016 Neurology Collaborators, 2019), the number of PD cases is expected to grow to over 12 million by 2040 (GBD 2016 Neurology Collaborators, 2019; Dorsey et al., 2018).

Age is the biggest risk factor to PD, and sex is a contributing factor with men being disproportionately affected (Wright Willis et al., 2010; Van Den Eeden, 2003). A wide number of studies have shown that known and unknown environmental factors can contribute to PD risk. Environmental factors such as pesticide exposure, well water consumption, and head injury, as well as premotor symptoms including constipation and depression among others (Noyce et al., 2012), have been associated with increased risk for PD (van der Mark et al., 2012), while other factors such as tobacco, coffee, and alcohol usage have controversially shown possible protective associations with PD (Li et al., 2015; Liu et al., 2012; Zhang et al., 2014).

2. The genetics of Parkinson's disease in the pre-GWAS and GWAS era

2.1. Monogenic Parkinson's disease

Historically, PD was considered a sporadic disorder in which environmental factors and age were the main risk factors. Indeed, before

the 1990s, there was significant doubt that PD had any heritability (Duvoisin, 1984). However, family history of PD (first degree relative definition) is found in approximately 15% of the patients and 5–10% of PD patients follow a classical Mendelian inheritance pattern (Lesage and Brice, 2009).

Since the discovery of disease causing mutations in *SNCA* in a large Italian kindred and three unrelated Greek families in the late nineties (Polymeropoulos, 1997), several genes have been linked to both autosomal dominant and recessive familial PD. However, only *SNCA, LRRK2, VPS35, PRKN, PINK1, GBA* and *DJ-1* have been convincingly associated with typical PD (Fig. 1). It is noteworthy that additional genes harbor rare mutations that lack replication and functional validation, and thus should be considered putative. Despite the high disease penetrance of familial cases, known monogenic loci only explain a small fraction of the observed familial aggregation of PD, suggesting that much remains to be found, likely in both genetic and non-genetic domains.

Apart from the widely reviewed genes involved in Mendelian PD, recent findings have nominated *TMEM230, LRP10, NUS1* and *ARSA* as putative disease-causing candidates. In 2016, Deng and colleagues identified *TMEM230* as the disease-causing gene in the same Canadian family where mutations in *DNAJC13* had been previously found to be causative (Deng et al., 2016; Vilariño-Güell et al., 2014). Three other PD-associated *TMEM230* variants were detected in 7 additional Chinese families (Deng et al., 2016). However, many other studies, including large series of PD patients, have failed to replicate this association (Yan et al., 2017; Giri et al., 2017; He et al., 2017; Baumann et al., 2017; Wu et al., 2017; Quadri et al., 2017; Buongarzone et al., 2017; Yang et al., 2017; Shi et al., 2017; Wei et al., 2018; Ibanez et al., 2017; Ma et al.,

2017; Fan et al., 2017; Conedera et al., 2018; Tejera-Parrado et al., 2018); thus, casting doubt on its implication in PD etiology (Iqbal and Toft, 2019; Deng et al., 2019; Farrer, 2019).

Genome-wide linkage analysis of a large Italian family with 13 members affected by autosomal-dominant PD and one affected by dementia with Lewy bodies (DLB) led to the identification of heterozygous variants in *LRP10* associated with PD, PD dementia (PDD), and DLB (Quadri et al., 2018). Further screening of *LRP10* in an international cohort of 660 probands revealed 8 additional rare and potentially-pathogenic *LRP10* variants (Quadri et al., 2018). Therefore, *LRP10* together with *SNCA, LRRK2,* and *GBA,* would support the idea that PD, PDD and DLB are parts of a continuum of Lewy body disease (Langston et al., 2015; Jellinger and Korczyn, 2018). However, replication of this association in different populations remains inconsistent (Kia, Sabir, et al., 2018b; Guerreiro et al., 2018; Pihlstrøm et al., 2018; Tesson et al., 2018; Shi et al., 2018; Chen et al., 2019; Vergouw et al., 2019), and further studies are needed to determine the involvement of *LRP10* in PD pathogenesis.

NUS1 has been nominated as a possible candidate gene for PD in the Han Chinese population (Guo et al., 2018). Guo et al. performed whole-exome sequencing of 39 EOPD patients, their parents and 20 unaffected siblings in order to investigate the effects of *de novo* mutations in PD. They identified 12 genes with plausible functional relevance to PD pathogenesis. Further analyses in two independent case-control cohorts found a significant association between *NUS1* and PD (*p*-value combined = 1.01×10^{-5}). Subsequent functional studies on *Drosophila* demonstrated that the loss of *NUS1* affects climbing ability, dopamine level and the number of dopaminergic neurons; thus, supporting a potential link between *NUS1* and PD pathogenesis (Guo et al., 2018).


Fig. 1. The genetics of Parkinson disease over time.
Red squares represent genome-wide association studies and number of discovered risk loci in brackets. * indicate genes associated with atypical parkinsonism related syndromes. Grey circles represent controversial or not widely validated genes linked to typical Parkinson disease

Fig. 2. Characterizing the genetic architecture of Parkinson disease.

NUS1 encodes the Nogo-B receptor (NgBR) that is a type I single transmembrane domain specific receptor for the neural and cardiovascular regulator Nogo-B. Mutations in *NUS1* have been previously associated with a congenital disorder of glycosylation (Park et al., 2014) and epileptic encephalopathies (Hamdan et al., 2017). It is also involved in intracellular cholesterol trafficking by interacting and stabilizing Niemann-Pick type C2 protein (NPC2) (Harrison et al., 2009). Although a recent study does not support a role for *NPC1/2* mutations in the pathogenesis of PD (Zech et al., 2013), the association between cholesterol and PD risk has been suggested in multiple studies (Klemann et al., 2017; Arenas et al., 2017; García-Sanz et al., 2017; Huang et al., 2019).

More recently, pathogenic and protective mutations in the arylsulfatase A gene (*ARSA*) have been linked to PD (Lee et al., 2019). The authors analyzed *ARSA* mutations in a family with a history of PD and identified two compound heterozygous missense mutations. *ARSA* encodes a lysosomal hydrolase and its complete deficiency causes metachromatic leukodystrophy, an autosomal recessive lysosomal storage disease. Therefore, these data provide additional support for the lysosomal system in PD pathogenesis (Klein and Mazzulli, 2018; Robak et al., 2017). Further screening in 92 familial and 92 sporadic PD cases did not detect additional pathogenic *ARSA* variants, but identified a non-synonymous variant that was proposed to be protective (J. S. Lee et al., 2019). Interestingly, the authors found that ARSA acts as a cytosolic molecular chaperone regulating α-synuclein accumulation and propagation. However, large international consortiums have failed to replicate the association between *ARSA* and PD (Makarious et al., 2019).

The number of familial and early onset cases with no known genetic cause remains high, and as demonstrated above, the validation of novel genes associated with PD remains extremely challenging. Families harboring rare genetic variants are uncommon and globally dispersed, thus making replication of segregating mutations or mutations in the same gene difficult. Further, modern genetic approaches such as whole genome sequencing remain expensive and are not always readily available. A logical path to solving this challenge is the creation of a global resource for mutation discovery, which democratizes the analysis of rare, but highly valuable families.

2.2. Sporadic Parkinson's disease

Only a small percentage of sporadic PD cases harbor mutations in known PD genes. Over the past decade, many studies have pursued the '*common disease-common variant*' (CDCV) hypothesis, which postulates that the genetic component of most common and complex disorders, such as PD, is due to a large number of common low-risk alleles (Lohmueller et al., 2003). Genome-wide association (GWA) studies are the gold-standard tool for testing the CDCV hypothesis. The first GWAS in PD to identify genome wide significant associations were reported in 2009. The first consisted of 5074 cases and 8551 controls of European origin (Simón-Sánchez et al., 2009). The authors identified two strong association signals, one in *SNCA* and the other in *MAPT* locus, as major risk factors for PD (Simón-Sánchez et al., 2009). The second, a GWA in an ancestral Asian population, replicated association at *SNCA* and identified 3 additional PD susceptibility loci, including *PARK16*, *LRRK2* and *BST1* (Satake et al., 2009). Since then, numerous GWA studies with increasing number of participants have been performed across populations (Kara et al., 2014; Siitonen et al., 2017; Bandres-Ciga et al., 2019b). The last and largest PD GWAS to date including around 37,700 cases, 18,600 'proxy' cases and 1.4 million controls has robustly identified 90 independent risk signals associated with sporadic PD (Nalls et al., 2019) (Fig. 2).

In spite of the success of GWA at expanding our understanding of the genetic basis of human complex diseases, for most traits, including PD, the associated loci do not account for all the genetic variance underlying the disease (Manolio et al., 2009). Analysis of common genetic variability suggests that only ~22% of the liability for PD is driven by these variants and the known associated GWAS SNPs only represent a fraction of this detected heritability (Nalls et al., 2019). Different explanations for the 'missing heritability problem' have been proposed

(Young, 2019; Génin, 2019). First, GWA analyses are not currently powered to capture all of the common genetic variability contributing to disease susceptibility, particularly those that may be rare and/or have small effect sizes. Increasing sample sizes of GWA allows researchers to identify new susceptibility loci in situations where statistical power is low and therefore may improve the proportion of explained heritability. It is also worth noting that rare variants of both large and small effect, and some structural variation, are not well-captured by GWA chips and imputation. There is increasing evidence that these may indeed play a major role in common diseases (Gibson, 2012; Bomba et al., 2017; Yang et al., 2015; Weissbrod et al., 2019). In addition, gene-gene and gene-environment interactions could also be contributing to common disease susceptibility (Zuk et al., 2012; Cordell, 2009; Ritchie and Van Steen, 2018; Cannon and Timothy Greenamyre, 2013). In PD, there is scant evidence for epistatic interactions, although this is a common theme in disease genetics because of the extreme sample sizes required to reliably detect such associations (Fernández-Santiago et al., 2019; Pecanka et al., 2017; Kuwahara et al., 2016; Beilina et al., 2014; Göbel et al., 2012). It is noteworthy however, that the explanation of epistasis as a piece of the missing heritability puzzle is controversial since dominance variance (due to genetic interactions) appears to have a minimal effect on heritability estimates and does not explain the missing heritability for some complex diseases (Zhu et al., 2015; Guerreiro et al., 2019; Diez-Fairen et al., 2019). Lastly, epigenetic factors can be transmitted through generations and thus may also contribute to disease risk (Bourrat et al., 2017; Trerotola et al., 2015; Cortijo et al., 2014; Bell and Spector, 2011).

2.3. Linking familial and sporadic forms of the disease

Besides identifying several risk loci for sporadic PD, large population-based GWAS and meta-analyses have also established that disease linked common variability exists at loci known to contain rare causal mutations. These include *SNCA, LRRK2, GBA* and *VPS13C*, previously associated with Mendelian forms of PD (Satake et al., 2009; Chang et al., 2017; Nalls et al., 2014; Simón-Sánchez et al., 2009); thus, suggesting a link between familial and sporadic forms of disease. These loci harboring both rare large effect and common smaller effect variants are known as pleomorphic risk loci (Singleton and Hardy, 2011). Therefore, both the CDCV hypothesis and the multiple rare variant hypothesis are not mutually exclusive. Instead, various disease-related genetic mechanisms may coexist at the same locus, each influencing disease through different biological effects on a single gene. For example, *SNCA* locus has been linked to PD etiology through: (i) duplications and triplications with a clear gene-dose effect (Singleton et al., 2003; Ibáñez et al., 2004; Chartier-Harlin et al., 2004); (ii) coding mutations causing early-onset PD familial cases (Krüger et al., 1998; Zarranz et al., 2004; Polymeropoulos, 1997; Lesage et al., 2013; Kiely et al., 2013; Pasanen et al., 2014); (iii) different association signals in GWAS illustrating the presence of low-effect common variability in this locus (Satake et al., 2009; Chang et al., 2017; Nalls et al., 2014; Simón-Sánchez et al., 2009); and (iv) non-coding risk/protective variants (Trotta et al., 2012).

3. Understanding the biological consequences of genetic risk

Many of the PD-related genes are involved in common biological pathways, which suggests that several critical cellular routes contribute to the disease risk. Mitochondrial dysfunction was one of the first biological processes to be associated with PD pathogenesis through the analysis of the recessive Mendelian genes. *PINK1*, a mitochondrial kinase, and *PRKN*, an E3 ubiquitin ligase, converge in the mitophagy pathway where *PINK1* phosphorylates *PRKN* to eliminate damaged mitochondria (Kane et al., 2014; Park et al., 2006; Clark et al., 2006). *DJ-1*, another ubiquitin ligase, promotes *PINK1* transcriptional activity and is also involved in mitochondrial physiology (Requejo-Aguilar

et al., 2015; Cookson, 2010). Other genes previously linked to classical and atypical PD risk such as *FBXO7, PLA2G6, VPS13C* and *CHCHD2*, have also been linked to the mitochondrial quality control system (Burchell et al., 2013; Lesage et al., 2016; Funayama et al., 2015; Lee et al., 2018; Cieri et al., 2017). A recent study estimated that common variation within the mitochondria function associated genes can contribute around 7% of the overall heritability (22%) of PD and that mitochondrial processes are involved in both monogenic and sporadic PD pathogenesis and contribute to later age at onset (Billingsley et al., 2019).

Pathway-based analyses have started to be implemented in PD research in order to identify biological processes that contribute to the disease. Recent studies have pointed out a high genetic risk burden for PD in the lysosomal and endocytic membrane trafficking pathways (Robak et al., 2017; Bandres-Ciga et al., 2019a). The immune response is another pathway that has been strongly associated with PD susceptibility (Zhang et al., 2017; Holmans et al., 2013), through both inflammation and autoimmune response. In fact, major histocompatibility complex (MHC) proteins are displayed on dopamine neurons of the substantia nigra, suggesting that antigenic epitopes could activate T cells involved in autoimmune responses and cell death (Garretti et al., 2019). Previous PD GWAS have identified risk loci spanning key immune associated genes such as *BST1* (bone marrow stromal cell antigen 1) and *HLA* (human leukocyte antigen) (Satake et al., 2009; Nalls et al., 2014). *BST1* has been proposed to play a role in neutrophil adhesion and migration, and it has been reported that it could be a cause of selective vulnerability of dopaminergic neurons in PD (Billingsley et al., 2018). Additionally, the *HLA* locus which encodes the MHC-II has been associated with PD (Nalls et al., 2019). GWAS have identified an association of PD with two MHC genes, including *HLA-DRB1* and *HLA-DRB5* (Hamza et al., 2010; Nalls et al., 2019). Indeed, it has been reported that α-synuclein-derived fragments act as antigenic epitopes displayed by *HLA* receptors, where both helper and cytotoxic T-cell responses are present in a high percentage of patients when tested (Bandres-Ciga and Cookson, 2017; Sulzer et al., 2017). Further investigation of these pathways can provide novel insights into PD pathogenesis and uncover novel therapeutic targets.

4. Predicting risk, progression and defining etiological subtypes of disease

Individually GWA identified loci confer relatively small amounts of disease risk; however, the use of polygenic risk scores (PRS) affords the ability to attribute a total known genetic risk score to an individual by summing their collective genetic risk. To date, the PRS reveals that, collectively, the 90 susceptibility loci confer considerable risk for disease, with those in the top decile of genetic risk being 6-fold more likely to have PD than those in the lowest decile of genetic risk (Nalls et al., 2019). Additionally, by creating a composite risk score for PD diagnosis that combines the cumulative effect of genetic risk variants as well as the presence or absence of anosmia, age, sex, and family history, the ability to predict individuals at high risk for PD is remarkable, showing an AUC sensitivity of ~83.4% and specificity of ~90% (Nalls et al., 2015b).

Research focused on age at onset disease modifiers is one area where consistent effort has been seen. The largest PD age at onset GWAS to date (Blauwendraat et al., 2019) included data from >25 K cases and identified two GWAS significant signals; one at *SNCA* and the other was a protein-coding variant in *TMEM175*, both of which are known PD risk loci. Notably, these results showed that not all PD risk loci influence age at onset and therefore suggest the idea that risk and onset might operate through mechanisms that do not completely overlap.

Despite the progress made in dissecting risk and understanding onset due to the availability of large sets of samples for genome-wide assessment, for the most part, these cohorts lack substantial clinical

data, making it difficult to investigate progression in a well-powered manner. Collecting comprehensive longitudinal data is costly, and harmonizing and combining individually small sample sets is time consuming and challenges. Despite these difficulties, the latest PD progression GWAS to date (Iwaki et al., 2019), managed to identify two GWAS signals in loci not previously linked to PD risk (*SLC44A1* associated with a faster rate of progression *via* Hohn and Yar score, and an intergenic variant related to *ADRA2A* expression associated with insomnia) (https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/).

Although laborious, accurate models of disease progression will enable the next generation of clinical trials. In recent years, several initiatives such as the Parkinson's Progression Markers Initiative (PPMI) (https://www.ppmi-info.org/), the Parkinson's Disease Biomarkers Program (PDBP) (https://pdbp-demo.cit.nih.gov/), Predict PD (Noyce et al., 2017b), and the Accelerating Medicines Partnership for Parkinson's disease (AMP-PD) (https://www.nih.gov/research-training/accelerating-medicines-partnership-amp) have emerged as valuable resources to aggregate and harmonize efforts in PD.

Predicting the precise clinical, molecular, and pathological subtypes in such a complex and heterogeneous disorder, will prove invaluable and will likely have an impact on drug development, therapeutic testing, and ultimately treatment (Leonard et al., 2019).

5. Inferring causal relationships across phenotypic traits and exploring shared polygenic risk

A corollary of abundant GWA data is the ability to test other traits that can predispose or protect individuals to disease. Access to large amounts of GWA data affords the opportunity to explore causal inferences between myriad traits and PD through Mendelian Randomization (MR), the gold standard approach for causality in genetic studies that sits at the interface between observational epidemiology and interventional trials (Lawlor et al., n.d.). MR has emerged as a statistical approach that uses genetic data in the form of SNPs to study whether an exposure exerts a causal effect in an outcome. This addresses the question of whether an observational association between a risk or protective factor and a disease of interest is consistent with a causal effect by focusing usually only on genome-wide significant SNPs. Put simply, genetic variants that explain variation in a certain exposure can be used as proxies to determine how a change in that exposure might influence a disease outcome. One of the key strengths of this method is that it relies on genetic variants that remain constant over the lifespan of an individual, are randomized during gametogenesis and fixed at conception, which means that genetic variants are not associated with all the confounder factors that affect an observational study.

In the PD field, two-sample MR has been applied considering both targeted (hypothesis-driven) exploration of causal associations, as well as hypothesis-generating approaches in a large-scale, high-throughput, unbiased manner.

For the former, an inverse causal association between body mass index (BMI) and risk of PD has been reported. A genetically-estimated 5 kg/m^2 higher BMI was associated with a reduced risk of PD (Noyce et al., 2017a). Negative causal associations have also been necessary to refute spurious associations. For instance, observational studies have reported that modulating plasma urate could be a potential preventive avenue for PD (Noyce et al., 2012; Bellou et al., 2016). However, MR did not find evidence for a causal protective effect of urate levels on PD risk (Kia et al., 2018a), corroborating the results from the Phase III of the SURE-PD3 clinical trial. The randomized, placebo-controlled, double-blinded trial conducted nationwide at 57 clinical sites of the Parkinson Study Group (PSG), failed at demonstrating that a treatment with Inosine raised blood levels of the natural antioxidant urate and therefore these molecular changes could slow the rate of progression in PD.

For the latter, a useful interactive resource for the PD community has been made publicly available (https://pdgenetics.shinyapps.io/pdgenetics) (Noyce et al., 2019). By using the PD MR Research Portal, users can search for evidence of causality on a broad range of exposures from 5839 different GWASes. This resource can be used to provide evidence to support, and over time, evidence against, causality when undertaking observational studies or pursuing interventions aimed at reducing the risk of PD.

To date, the main limitations of applying MR, is that many studies are underpowered, either as a consequence of relatively low samples sizes in the exposure GWAS data or the small amount of variation (heritability) in an exposure trait that is explained by the reported common genetic variation.

Another approach that has recently taken importance is applying Linkage disequilibrium score regression (LDSC) to investigate the extent to which genetic etiologies are shared across different diseases. In the PD genetics field, it has been successfully implemented to test whether polygenic risk contributing to a phenotype of interest might also contribute to the risk of PD. Cross-trait genetic correlations between the latest PD GWAS (Nalls et al., 2019) summary statistics and 757 other GWAS available datasets revealed four significant genetic correlations, including positive correlations with intracranial volume and putamen volume (suggesting that both may prove to be valuable PD biomarkers) and negative correlations with current tobacco use and "academic qualifications: National Vocational Qualifications (NVQ) or Higher National Diploma (HND) or Higher National Certificate (HNC) or equivalent". Interestingly, the negative association with one's academic qualifications indicates that those individuals without a college education may have a lower likelihood of developing PD than individuals with higher levels of education, but again, correlation does not imply causation. Although there remains a lot to be done, the current work represents a novel approach towards the foundation to pursue PD research in the Post-GWAS era.

6. Translating genetics into precision medicine

6.1. Pharmacogenetics

The decrease in genetic testing cost has positioned precision medicine, medical practice specifically attuned to genetics of the individual patient, as the focus of clinical genetics research and the US health care policy (Collins and Varmus, 2015). Genetics-informed personalized therapeutics, also called pharmacogenetics, are the future of healthcare, and already an indication for drug usage and dosing. Currently, there are clinical trials that take into account crucial genes associated with PD such as *GBA* (Silveira et al., 2019) and *LRRK2* (Chen et al., 2018; Whiffin et al., n.d.).

As one of the most well understood PD risk genes, *GBA* is frequently seen as a treatment target. In general, *GBA* carrier PD cases present worse disease symptoms and mutation severity has been associated with differences in age-at-onset (Brockmann et al., 2015; Gan-Or et al., 2018). For instance, *GBA* p.N370S variant is known to increase PD risk and when homozygous cause Gaucher Disease (GD) (Clark et al., 2005). In the largest PD age at onset GWAS to date, significant hits within the *GBA* region were variants p.N370S, p.E326K, and p.T369 M with effect sizes between 2.6 and 0.9 year reduction in age-at-onset (Blauwendraat et al., 2019). In a longitudinal study, PD patients with *GBA* variants that cause neuropathic GD have shown to have accelerated cognitive decline over time compared to other PD patients (Liu et al., 2016). Despite these findings, the role and the mechanism of *GBA* and its product Glucocerebrosidase (GCase) remains unclear. In addition, many *GBA* carriers never get PD. *GBA* modifiers may help answer this conundrum. PD PRS is higher in *GBA* carrier cases compared to carrier controls, with variants near *CTSB* and *SNCA* showing potential gene-gene interaction with *GBA* (Blauwendraat et al., 2020). Nevertheless, clinical trials have started for *GBA* targeted therapies, all trying increase GCase production or activity. One uses glucosylceramide synthase inhibitor GZ/SAR402671 (ClinicalTrials.gov identifier NCT02906020), while others

are using ambroxol hydrochloride (ClinicalTrials.gov identifier NCT02941822 and NCT02914366).

Patient-specific dosage and management of side effects is an important aspect of personalized medicine. Genes that influence the patient response often are involved in pathways that interact with the treatment in question. Many of the current PD treatments focus on supplying the brain with additional dopamine, either by providing the body with precursor molecules (levodopa), metabolic enzyme inhibitors (rasagiline), or dopamine receptor agonists (ropinirole). As such, genes associated with treatment effectiveness are involved in pathways that interact with dopamine and metabolism of dopamine precursors. For instance, *DDC* and *COMT* encode enzymes that metabolize levodopa to dopamine, and variations in both are associated with dosage and side effects of levodopa (Bialecka et al., 2008; de Lau et al., 2012; Cheshire et al., 2014). Dopamine transporter gene *DAT* has been associated with psychosis with levodopa treatment (Kaiser et al., 2003) and dopamine receptor genes, including *DRD2* and *DRD3*, have been associated with side effects in levodopa and MAO-B inhibitors (Masellis et al., 2016; Rieck et al., 2012; Krishnamoorthy et al., 2016). In addition, there is evidence that monogenic PD patients have varied response to deep brain stimulation therapy (DBS) depending on the gene and variant in question; the *LRRK2* p.G2019S variant has shown positive outcomes to DBS, while *LRRK2* p.R1441G has shown poor outcomes (Kuusimäki et al., 2019).

7. Future directions

7.1. Genomics need diversity

Most work in genomics has been done in subjects of Northern European Ancestry (Popejoy and Fullerton, 2016) and PD genetic research is no exception (Foo et al., 2017). This lack of diversity reveals three limitations of our current approach: We don't understand the applicability of genetic risk and PRS across populations; the LD structure of a single ancestral group means that it is difficult to fine map risk loci, and there is missing novel ancestry underlying specific genetic risk.

Expanding our investigation to more diverse populations is the right thing to do. Given our discussion of the potential impact of individualized genetic risk on treatment, it is critical that we understand genetic risk in individuals of varied genetic backgrounds, so that we can treat everyone effectively. A clear benefit of the expansion of this effort is the potential to identify rare but informative ancestry specific risk alleles and the genes these alleles influence, providing new therapeutic targets; however, this work also affords the ability to perform trans ethnic fine mapping, an approach that facilitates the reduction of risk regions to smaller credible intervals, thus simplifying their functional characterization.

Merely adding additional non-European participants will not be enough to remove the current bias. We will have to produce reference data and develop genetic tools specifically tailored to underserved populations. The current PD GWAS includes large amount of data from genotyping arrays designed around European populations (Nalls et al., 2015a; Blauwendraat et al., 2017; Bycroft et al., 2018). Designing arrays based on more global population or use of whole-genome sequencing in conjunction with diverse participant population will be crucial to reducing systematic European bias. Outside of PD, there has been at least one study on an underrepresented population that found a rare SNP with an effect on both the underrepresented and European populations (Fumagalli et al., 2015). In the same manner, PD may have "missing heritability" ready to be discovered through the study of non-European populations.

The good news is that there is a growing push to include diverse ancestral populations in genetics work. Pan-continental programs such as H3 Africa (H3Africa Consortium et al., 2014) have already begun establishing networks of international labs in genetically understudied

regions. In the United States, the *All of Us* initiative is building a diverse genetic database that encompasses the population of the United States, including historically underrepresented populations (Investigators and The All of Us Research Program Investigators, 2019). In the PD genetics field, pilot genomic studies have started to arise; the Michael J Fox Foundation (MJFF) has recently committed pilot support across non-European populations (Williams et al., 2018) including initiatives to extend large scale genotyping efforts to Latin Americans (LARGE-PD) (Zabetian, Mata, and Latin American Research Consortium on the Genetics of PD (LARGE-PD), 2017), Africans, African-Americans, the Luxembourg-German-Indian Alliance on Neurodegenerative diseases and Therapeutics (Lux GIANT) and East-Asians under the wing of the International Parkinson's disease Genomics Consortium (IPDGC; https://pdgenetics/org). We envisage that funding agencies will incentivize studying diverse populations and PD genetics research will make in-roads with non-European academia to establish collaborative large-scale genetic studies.

8. Conclusion

Within two decades, PD genetics has come a long way, from the field doubting the role of genetics in PD to an increased understanding its impact on PD risk, onset, progression, and treatment response, as well as phenotypic etiologies and causal comorbidities. Yet only a fraction of the heritability is known and the relationship between genetics and PD pathology is poorly understood. The nascent movement to expand this work at scale and to encourage diverse participation in PD genetics research will not only reduce systematic health disparities but also promote discoveries of the missing pieces of PD genetics.

Declaration of Competing Interest

The authors have nothing to disclose.

References

GBD 2016 Neurology Collaborators, 2019. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 18 (5), 459–480.

Ma, D., Foo, J.N., Ng, E.Y., Zhao, Y., Liu, J.-J., Tan, E.K., 2017. Screening for TMEM230 mutations in young-onset Parkinson's disease. Neurobiol. Aging 58 (October), 239.e9–239.e10.

Investigators, The All of Us Research Program, The All of Us Research Program Investigators, 2019. The 'All of Us' Research Program. N. Engl. J. Med. https://doi.org/10.1056/nejmsr1809937.

Deng, H.-X., Shi, Y., Yang, Y., Ahmeti, K.B., Miller, N., Huang, C., Cheng, L., et al., 2016. Identification of TMEM230 mutations in familial Parkinson's disease. Nat. Genet. 48 (7), 733–739.

Trerotola, Marco, Relli, Valeria, Simeone, Pasquale, Alberti, Saverio, 2015. Epigenetic inheritance and the missing heritability. Hum. Genomics 9 (July), 17.

Vilariño-Güell, C., Rajput, A., Milnerwood, A.J., Shah, B., Szu-Tu, C., Trinh, J., Yu, I., et al., 2014. DNAJC13 mutations in Parkinson disease. Hum. Mol. Genet. 23 (7), 1794–1801.

Zech, M., Nübling, G., Castrop, F., Jochim, A., Schulte, E.C., Mollenhauer, B., Lichtner, P., et al., 2013. Niemann-Pick C disease gene mutations and age-related neurodegenerative disorders. PLoS One 8 (12), e82879.

Arenas, F., Garcia-Ruiz, C., Fernandez-Checa, J.C., 2017. Intracellular cholesterol trafficking and impact in neurodegeneration. Front. Mol. Neurosci. 10 (November), 382.

Whiffin, Nicola, Irina M. Armean, Aaron Kleinman, Jamie L. Marshall, Eric V. Minikel, Julia K. Goodrich, Nicholas M. Quaife, et al. n.d. "Human loss-of-function variants suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson's

disease." doi:https://doi.org/10.1101/561472.

Bandres-Ciga, S., Cookson, M.R., 2017. Alpha-synuclein triggers T-Cell response. Is Parkinson's disease an autoimmune disorder? Mov. Disord. https://doi.org/10.1002/mds.27116.

Bandres-Ciga, S., Saez-Atienzar, S., Bonet-Ponce, L., Billingsley, K., Vitale, D., Blauwendraat, C., Gibbs, J.R., et al., 2019a. The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders 34 (4), 460–468.

Baumann, H., Wolff, S., Münchau, A., Hagenah, J.M., Lohmann, K., Klein, C., 2017. Evaluating the role of TMEM230 variants in Parkinson's disease. Parkinsonism Relat. Disord. 35, 100–101.

Beilina, A., Rudenko, I.N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S.K., Kalia, L.V., et al., 2014. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 111 (7), 2626–2631.

Bell, J.T., Spector, T.D., 2011. A twin approach to unraveling epigenetics. Trend. Genet. 27 (3), 116–125.

Bellou, V., Belbasis, L., Tzoulaki, I., Evangelou, E., Ioannidis, J.P.A., 2016. Environmental risk factors and Parkinson's disease: an umbrella review of meta-analyses. Parkinsonism Relat. Disord. https://doi.org/10.1016/j.parkreldis.2015.12.008.

Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A., Schulte, C., Maetzler, W., Gasser, T., Berg, D., 2015. GBA -associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord. https://doi.org/10.1002/mds.26071.

Bialecka, M., Kurzawski, M., Klodowska-Duda, G., Opala, G., Tan, E.-K., Drozdzik, M., 2008. The association of functional catechol-o-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet. Genomics 18 (9), 815–821.

Billingsley, K.J., International Parkinson's Disease Genomics Consortium (IPDGC), Barbosa, I.A., Bandrés-Ciga, S., Quinn, J.P., Bubb, V.J., Deshpande, C., et al., 2019. Mitochondria function associated genes contribute to Parkinson's disease risk and later age at onset. NPJ Parkinson's Dis. https://doi.org/10.1038/s41531-019-0080-x.

Billingsley, K.J., Bandres-Ciga, S., Saez-Atienzar, S., Singleton, A.B., 2018. Genetic risk factors in Parkinson's disease. Cell Tissue Res. 373 (1), 9–20.

Blauwendraat, C., Heilbron, K., Vallerga, C.L., Bandres-Ciga, S., von Coelln, R., Pihlstrøm, L., Simón-Sánchez, J., et al., 2019. Parkinson's disease age at onset genome-wide association study: defining heritability, genetic loci, and α-synuclein mechanisms. Movement Disorders 34 (6), 866–875.

Blauwendraat, C., Reed, X., Krohn, L., Heilbron, K., Bandres-Ciga, S., Tan, M., Raphael Gibbs, J., et al., 2020. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain J. Neurol. 143 (1), 234–248.

Bomba, L., Walter, K., Soranzo, N., 2017. The impact of rare and low-frequency genetic variants in common disease. Genome Biol. 18 (1), 77.

Bourrat, Pierrick, Lu, Qiaoying, Jablonka, Eva, 2017. Why the missing heritability might not be in the DNA. BioEssays. https://doi.org/10.1002/bies.201700067.

Liu, G., Boot, B., Locascio, J.J., Jansen, I.E., Winder-Rhodes, S., Eberly, S., Elbaz, A., et al., 2016. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Ann. Neurol. https://doi.org/10.1002/ana.24781.

Lesage, S., Brice, A., 2009. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18 (R1), R48–R59.

Burchell, V.S., Nelson, D.E., Sanchez-Martinez, A., Delgado-Camprubi, M., Ivatt, R.M., Pogson, J.H., Randle, S.J., et al., 2013. The Parkinson's disease–linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat. Neurosci. https://doi.org/10.1038/nn.3489.

Cortijo, S., Wardenaar, R., Colomé-Tatché, M., Gilly, A., Etcheverry, M., Labadie, K., Caillieux, E., et al., 2014. Mapping the epigenetic basis of complex traits. Science 343 (6175), 1145–1148.

Cannon, J.R., Timothy Greenamyre, J., 2013. Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol. Dis. 57 (September), 38–46.

Chang, D., Nalls, M.A., Hallgrímsdóttir, I.B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, et al., 2017. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat. Genet. 49 (10), 1511–1516.

Chen, J., Chen, Y., Pu, J., 2018. Leucine-rich repeat kinase 2 in Parkinson's disease: updated from pathogenesis to potential therapeutic target. Eur. Neurol. https://doi.org/10.1159/000488938.

Chen, Y., Cen, Z., Zheng, X., Pan, Q., Chen, X., Zhu, L., Si, C., et al., 2019. LRP10 in autosomal-dominant Parkinson's disease. Movement Disorders 34 (6), 912–916.

Cheshire, P., Bertram, K., Ling, H., O'Sullivan, S.S., Halliday, G., McLean, C., Bras, J., Foltynie, T., Storey, E., Williams, D.R., 2014. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. Neurodegener. Dis. 13 (1), 24–28.

Cieri, D., Brini, M., Calì, T., 2017. Emerging (and Converging) pathways in Parkinson's disease: keeping mitochondrial wellness. Biochem. Biophys. Res. Commun. 483 (4), 1020–1030.

Clark, L.N., Nicolai, A., Afridi, S., Harris, J., Mejia-Santana, H., Strug, L., Cote, L.J., et al., 2005. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Movement Disorders 20 (1), 100–103.

Clark, I.E., Dodson, M.W., Jiang, C., Cao, J.H., Huh, J.R., Seol, J.H., Yoo, S.J., Hay, B.A., Guo, M., 2006. Drosophila pink1 is required for mitochondrial function and interacts genetically with Parkin. Nature 441 (7097), 1162–1166.

Collins, F.S., Varmus, H., 2015. A new initiative on precision medicine. N. Engl. J. Med. https://doi.org/10.1056/nejmp1500523.

Conedera, S.A., Li, Y., Funayama, M., Yoshino, H., Nishioka, K., Hattori, N., 2018. Genetic

analysis of TMEM230 in Japanese patients with familial Parkinson's disease. Parkinsonism Relat. Disord. 48 (March), 107–108.

H3Africa Consortium, Rotimi, C., Abayomi, A., Abimiku, A. 'le, Adabayeri, V.M., Adebamowo, C., Adebiyi, E., et al., 2014. Research capacity. enabling the genomic revolution in Africa. Science 344 (6190), 1346–1348.

Cookson, M.R., 2010. DJ-1, PINK1, and their effects on mitochondrial pathways. Movement Disorders 25 (Suppl. 1), S44–S48.

Cordell, H.J., 2009. Detecting gene-gene interactions that underlie human diseases. Nat. Rev. Genet. 10 (6), 392–404.

Ibanez, L., Dube, U., Budde, J., Black, K., Medvedeva, A., Davis, A.A., Perlmutter, J.S., Benitez, B.A., Cruchaga, C., 2017. TMEM230 in Parkinson's disease. Neurobiol. Aging 56 (August), 212.e1–212.e3.

Deng, H.-X., Pericak-Vance, M.A., Siddique, T., 2019. Reply to 'TMEM230 variants in Parkinson's disease' and 'doubts about TMEM230 as a gene for Parkinsonism. Nat. Genet. 51 (3), 369–371.

Diez-Fairen, Monica, Bandres-Ciga, Sara, Houle, Gabrielle, Nalls, Mike A., Girard, Simon L., Dion, Patrick A., Blauwendraat, Cornelis, Singleton, Andrew B., Rouleau, Guy A., Pastor, Pau, 2019. Genome-wide estimates of heritability and genetic correlations in essential tremor. Parkinsonism Relat. Disord. https://doi.org/10.1016/j.parkreldis.2019.05.002. May.

Dorsey, E.R., Sherer, T., Okun, M.S., Bloem, B.R., 2018. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 8 (s1), S3–S8.

Duvoisin, R.C., 1984. Is Parkinson's disease acquired or inherited? J. Can. Sci. Neurol. 11 (S1), 151–155.

Fan, T.-S., Lin, C.-H., Lin, H.-I., Chen, M.-L., Wu, R.-M., 2017. Lack of TMEM230 mutations in patients with familial and sporadic Parkinson's disease in a Taiwanese population. Am. J. Med. Genet. B Neuropsych. Genet. 174 (7), 751–756.

Farrer, M.J., 2019. Doubts about TMEM230 as a gene for Parkinsonism. Nat. Genet. 51 (3), 367–368.

Fernández-Santiago, R., Martín-Flores, N., Antonelli, F., Cerquera, C., Moreno, V., Bandres-Ciga, S., Manduchi, E., et al., 2019. SNCA and mTOR pathway single nucleotide polymorphisms interact to modulate the age at onset of Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.27770. June.

Foo, J.N., Tan, L.C., Irwan, I.D., Wing-Lok, A., Low, H.Q., Prakash, K.-M., Ahmad-Annuar, A., et al., 2017. Genome-wide association study of Parkinson's disease in East Asians. Hum. Mol. Genet. 26 (1), 226–232.

Fumagalli, M., Moltke, I., Grarup, N., Racimo, F., Bjerregaard, P., Jørgensen, M.E., Korneliussen, T.S., et al., 2015. Greenlandic Inuit show genetic signatures of diet and climate adaptation. Science 349 (6254), 1343–1347.

Gan-Or, Z., Liong, C., Alcalay, R.N., 2018. GBA-associated Parkinson's disease and other synucleinopathies. Curr. Neurol. Neurosci. Rep. https://doi.org/10.1007/s11910-018-0860-4.

García-Sanz, P., Orgaz, L., Bueno-Gil, G., Espadas, I., Rodríguez-Traver, E., Kulisevsky, J., Gutierrez, A., et al., 2017. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease. Movement Disorders 32 (10), 1409–1422.

Garretti, F., Agalliu, D., Lindestam, C.S., Arlehamn, A.S., Sulzer, D., 2019. Autoimmunity in Parkinson's disease: the role of α-synuclein-specific T cells. Front. Immunol. 10 (February), 303.

Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., et al., 2018. The UK Biobank resource with deep phenotyping and genomic data. Nature 562 (7726), 203–209.

Blauwendraat, Cornelis, Faghri, Faraz, Pihlstrom, Lasse, Geiger, Joshua T., Elbaz, Alexis, Lesage, Suzanne, Corvol, Jean-Christophe, et al., 2017. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol. Aging 57 (September), 247.e9–247.e13.

Génin, Emmanuelle, 2019. Missing heritability of complex diseases: case solved? Hum. Genet. https://doi.org/10.1007/s00439-019-02034-4. June.

Gibson, G., 2012. Rare and common variants: twenty arguments. Nat. Rev. Genet. 13 (2), 135–145.

Göbel, A., Macklin, E.A., Winkler, S., Betensky, R.A., Klein, C., Lohmann, K., Simon, D.K., 2012. Genetic risk factors in Parkinson's disease: single gene effects and interactions of genotypes. J. Neurol. 259 (11), 2503–2505.

Park, E.J., Grabińska, K.A., Guan, Z., Stránecký, V., Hartmannová, H., Hodaňová, K., Barešová, V., et al., 2014. Mutation of Nogo-B receptor, a subunit of Cis-prenyltransferase, causes a congenital disorder of glycosylation. Cell Metab. 20 (3), 448–457.

Guerreiro, Rita, Orme, Tatiana, Neto, João Luís, Bras, Jose, International DLB Genetics Consortium, 2018. LRP10 in α-synucleinopathies. Lancet Neurol. 17 (12), 1032–1033.

Guerreiro, R., Escott-Price, V., Hernandez, D.G., Kun-Rodrigues, C., Ross, O.A., Orme, T., Neto, J.L., et al., 2019. Heritability and genetic variance of dementia with Lewy bodies. Neurobiol. Dis. 127 (July), 492–501.

Guo, J.-F., Zhang, L., Li, K., Mei, J.-P., Xue, J., Chen, J., Tang, X., et al., 2018. Coding mutations in contribute to Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 115 (45), 11567–11572.

Hamdan, F.F., Myers, C.T., Cossette, P., Lemay, P., Spiegelman, D., Laporte, A.D., Nassif, C., et al., 2017. High rate of recurrent de novo mutations in developmental and epileptic encephalopathies. Am. J. Hum. Genet. 101 (5), 664–685.

Hamza, T.H., Zabetian, C.P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D.M., et al., 2010. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. https://doi.org/10.1038/ng.642.

Harrison, K.D., Miao, R.Q., Fernandez-Hernándo, C., Suárez, Y., Dávalos, A., Sessa, W.C., 2009. Nogo-B receptor stabilizes Niemann-Pick type C2 protein and regulates intracellular cholesterol trafficking. Cell Metab. 10 (3), 208–218.

He, Y.-C., Huang, P., Li, Q.-Q., Sun, Q., Li, D.-H., Wang, T., Shen, J.-Y., Chen, S.-D., 2017. TMEM230 stop codon mutation is rare in Parkinson's disease and essential tremor in

Eastern China. Movement Disorders 32 (2), 301–302.

Holmans, P., Moskvina, V., Jones, L., Sharma, M., International Parkinson's Disease Genomics Consortium, Vedernikov, A., Buchel, F., et al., 2013. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum. Mol. Genet. 22 (5), 1039–1049.

Huang, X., Sterling, N.W., Guangwei, D., Sun, D., Stetter, C., Kong, L., Zhu, Y., et al., 2019. Brain cholesterol metabolism and Parkinson's disease. Movement Disorders 34 (3), 386–395.

Ibáñez, P., A-M Bonnet, B., Débarges, E., Lohmann, F., Tison, P., Pollak, Y., Agid, A.D., Brice, A., 2004. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364 (9440), 1169–1171.

Iqbal, Z., Toft, M., 2019. TMEM230 variants in Parkinson's disease. Nat. Genet. 51, 366.

Iwaki, H., Blauwendraat, C., Leonard, H.L., Kim, J.J., Liu, G., Maple-Grødem, J., Corvol, J.-C., et al., 2019. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders 34 (12), 1839–1850.

Jellinger, K.A., Korczyn, A.D., 2018. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? BMC Med. https://doi.org/10.1186/s12916-018-1016-8.

Zhang, D., Jiang, H., Xie, J., 2014. Alcohol intake and risk of Parkinson's disease: a meta-analysis of observational studies. Movement Disorders 29 (6), 819–822.

Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J., Tienari, P.J., Pöyhönen, M., Paetau, A., 2014. Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 35 (9) (2180.e1–5).

Kaiser, R., Hofer, A., Grapengiesser, A., Gasser, T., Kupsch, A., Roots, I., Brockmöller, J., 2003. L-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60 (11), 1750–1755.

Kane, L.A., Lazarou, M., Fogel, A.I., Li, Y., Yamano, K., Sarraf, S.A., Banerjee, S., Youle, R.J., 2014. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J. Cell Biol. 205 (2), 143–153.

Kuwahara, T., Inoue, K., D'Agati, V.D., Fujimoto, T., Eguchi, T., Saha, S., Wolozin, B., Iwatsubo, T., Abeliovich, A., 2016. LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. Sci. Rep. 6 (July), 29945.

Kia, D.A., Noyce, A.J., White, J., Speed, D., Nicolas, A., collaborators, I.P.D.G.C., Burgess, S., et al., 2018a. Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson's disease. Ann. Neurol. 84 (2), 191–199.

Kia, D.A., Sabir, M.S., Ahmed, S., Trinh, J., Bandres-Ciga, S., International Parkinson's Disease Genomics Consortium, 2018b. LRP10 in α-Synucleinopathies. Lancet Neurol. 17 (12), 1032.

Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., et al., 2013. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 125 (5), 753–769.

Klein, A.D., Mazzulli, J.R., 2018. Is Parkinson's disease a lysosomal disorder? Brain J. Neurol. 141 (8), 2255–2262.

Klemann, C.J.H., Martens, G.J.M., Sharma, M., Martens, M.B., Isacson, O., Gasser, T., Visser, J.E., Poelmans, G., 2017. Integrated molecular landscape of Parkinson's disease. NPJ Parkinson's Dis. 3 (1), 14.

Krishnamoorthy, S., Rajan, R., Banerjee, M., Kumar, H., Sarma, G., Krishnan, S., Sarma, S., Kishore, A., 2016. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients. Parkinsonism Relat. Disord. https://doi.org/10.1016/j.parkreldis.2016.06.005.

Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J.T., Schöls, L., Riess, O., 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (2), 106–108.

Kuusimäki, T., Korpela, J., Pekkonen, E., Martikainen, M.H., Antonini, A., Kaasinen, V., 2019. Deep brain stimulation for monogenic Parkinson's disease: a systematic review. J. Neurol. https://doi.org/10.1007/s00415-019-09181-8.

Langston, J.W., Schüle, B., Rees, L., Nichols, R.J., Barlow, C., 2015. Multisystem Lewy body disease and the other Parkinsonian disorders. Nat. Genet. 47 (12), 1378–1384.

de Lau, L.M.L., Verbaan, D., Marinus, J., Heutink, P., van Hilten, J.J., 2012. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. Movement Disorders 27 (1), 132–135.

Lawlor, Deborah A., Kaitlin Wade, Maria Carolina Borges, Tom Palmer, Fernando Pires Hartwig, Gibran Hemani, and Jack Bowden. n.d. "A Mendelian Randomization Dictionary: Useful Definitions and Descriptions for Undertaking, Understanding and Interpreting Mendelian Randomization Studies." doi:10.31219/osf.io/6yzs7.

Lee, Richard G., Sedghi, Maryam, Salari, Mehri, Shearwood, Anne-Marie J., Stentenbach, Maike, Kariminejad, Ariana, Goullee, Hayley, et al., 2018. Early-onset parkinson disease caused by a mutation in CHCHD2 and mitochondrial dysfunction. Neurol. Genet. 4 (5), e276.

Lee, J.S., Kanai, K., Suzuki, M., Kim, W.S., Yoo, H.S., Yuhong, F., Kim, D.-K., et al., 2019. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone. Brain J. Neurol. https://doi.org/10.1093/brain/awz349. July.

Leonard, H., Blauwendraat, C., Krohn, L., Faghri, F., Iwaki, H., Furgeson, G., Day-Williams, A.G., et al., 2019. Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease. https://doi.org/10.1101/427385.

Lesage, S., Drouet, V., Majounie, E., Deramecourt, V., Jacoupy, M., Nicolas, A., Cormier-Dequaire, F., et al., 2016. Loss of VPS13C function in autosomal-recessive Parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy. Am. J. Hum. Genet. 98 (3), 500–513.

Li, X., Li, W., Liu, G., Shen, X., Tang, Y., 2015. Association between cigarette smoking and Parkinson's disease: a meta-analysis. Arch. Gerontol. Geriatr. https://doi.org/10.1016/j.archger.2015.08.004.

Yan, W., Tang, B., Zhou, X., Lei, L., Li, K., Sun, Q., Xu, Q., Yan, X., Guo, J., Liu, Z., 2017.

TMEM230 mutation analysis in Parkinson's disease in a Chinese population. Neurobiol. Aging 49 (January), 219.e1–219.e3.

Liu, R., Guo, X., Park, Y., Huang, X., Sinha, R., Freedman, N.D., Hollenbeck, A.R., Blair, A., Chen, H., 2012. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am. J. Epidemiol. 175 (11), 1200–1207.

Lohmueller, K.E., Pearce, C.L., Pike, M., Lander, E.S., Hirschhorn, J.N., 2003. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33 (2), 177–182.

Makarious, Mary B., Diez-Fairen, Monica, Krohn, Lynne, Blauwendraat, Cornelis, Bandres-Ciga, Sara, Ding, Jinhui, Pihlstrøm, Lasse, Houlden, Henry, Scholz, Sonja W., Gan-Or, Ziv, 2019. ARSA variants in α-synucleinopathies. Brain A J. Neurol. https://doi.org/10.1093/brain/awz340. October.

Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J., McCarthy, M.I., et al., 2009. Finding the missing heritability of complex diseases. Nature 461 (7265), 747–753.

van der Mark, M., Brouwer, M., Kromhout, H., Nijssen, P., Huss, A., Vermeulen, R., 2012. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ. Health Perspect. 120 (3), 340–347.

Giri, A., Mok, K.Y., Jansen, I., Sharma, M., Tesson, C., Mangone, G., Lesage, S., et al., 2017. Lack of evidence for a role of genetic variation in TMEM230 in the Risk for Parkinson's disease in the Caucasian population. Neurobiol. Aging 50 (February), 167.e11–167.e13.

Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., DeStefano, A.L., et al., 2014. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46 (9), 989–993.

Nalls, M.A., Bras, J., Hernandez, D.G., Keller, M.F., Majounie, E., Renton, A.E., Saad, M., et al., 2015a. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol. Aging 36 (3) (1605.e7–12).

Nalls, M.A., McLean, C.Y., Rick, J., Eberly, S., Hutten, S.J., Gwinn, K., Sutherland, M., et al., 2015b. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 14 (10), 1002–1009.

Siitonen, A., Nalls, M.A., Hernández, D., Raphael Gibbs, J., Ding, J., Ylikotila, P., Edsall, C., Singleton, A., Majamaa, K., 2017. Genetics of early-onset Parkinson's disease in Finland: exome sequencing and genome-wide association study. Neurobiol. Aging 53 (May), 195.e7–195.e10.

Nalls, M.A., Blauwendraat, C., Vallerga, C.L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., et al., 2019. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18 (12), 1091–1102.

Noyce, A.J., Bandres-Ciga, S., Kim, J., Heilbron, K., Kia, D., Hemani, G., Xue, A., et al., 2019. The Parkinson's disease mendelian randomization research portal. Movement Disorders. https://doi.org/10.1002/mds.27873. October.

Noyce, A.J., Bestwick, J.P., Silveira-Moriyama, L., Hawkes, C.H., Giovannoni, G., Lees, A.J., Schrag, A., 2012. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. https://doi.org/10.1002/ana.23687.

Noyce, A.J., Kia, D.A., Hemani, G., Nicolas, A., Ryan Price, T., De Pablo-Fernandez, E., Haycock, P.C., et al., 2017a. Estimating the causal influence of body mass index on risk of Parkinson disease: a Mendelian randomisation study. PLoS Med. 14 (6), e1002314.

Noyce, A.J., R'Bibo, L., Peress, L., Bestwick, J.P., Adams-Carr, K.L., Mencacci, N.E., Hawkes, C.H., et al., 2017b. PREDICT-PD: an online approach to prospectively identify risk indicators of Parkinson's disease. Movement Disorders 32 (2), 219–226.

Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., et al., 2006. Mitochondrial dysfunction in drosophila PINK1 mutants is complemented by Parkin. Nature 441 (7097), 1157–1161.

Pecanka, J., Jonker, M.A., International Parkinson'S Disease Genomics Consortium (IPDGC), Bochdanovits, Z., Van Der Vaart, A.W., 2017. A powerful and efficient two-stage method for detecting gene-to-gene interactions in GWAS. Biostatistics 18 (3), 477–494.

Pihlstrøm, L., Schottlaender, L., Chelban, V., Houlden, H., Exome Consortium, M.S.A., 2018. LRP10 in α-synucleinopathies. Lancet Neurol. 17 (12), 1033–1034.

Poewe, Werner, Seppi, Klaus, Tanner, Caroline M., Halliday, Glenda M., Brundin, Patrik, Volkmann, Jens, Schrag, Anette-Eleonore, Lang, Anthony E., 2017. Parkinson disease. Nat. Rev. Dis. Prim. https://doi.org/10.1038/nrdp.2017.13.

Polymeropoulos, M.H., 1997. Mutation in the -synuclein gene identified in families with Parkinson's disease. Science. https://doi.org/10.1126/science.276.5321.2045.

Popejoy, Alice B., Fullerton, Stephanie M., 2016. Genomics is failing on diversity. Nature 538 (7624), 161–164.

Quadri, M., Breedveld, G.J., Chang, H.-C., Yeh, T.-H., Guedes, L.C., Toni, V., Fabrizio, E., et al., 2017. Mutations in TMEM230 are not a common cause of Parkinson's disease. Movement Disorders 32 (2), 302–304.

Quadri, M., Mandemakers, W., Grochowska, M.M., Masius, R., Geut, H., Fabrizio, E., Breedveld, G.J., et al., 2018. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurol. 17 (7), 597–608.

Requejo-Aguilar, R., Lopez-Fabuel, I., Jimenez-Blasco, D., Fernandez, E., Almeida, A., Bolaños, J.P., 2015. DJ1 represses glycolysis and cell proliferation by transcriptionally up-regulating Pink1. Biochem. J. 467 (2), 303–310.

Rieck, M., Schumacher-Schuh, A.F., Altmann, V., Francisconi, C.L., Fagundes, P.T., Monte, T.L., Callegari-Jacques, S.M., Rieder, C.R., Hutz, M.H., 2012. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 13 (15), 1701–1710.

Ritchie, Marylyn D., Van Steen, Kristel, 2018. The search for gene-gene interactions in genome-wide association studies: challenges in abundance of methods, practical considerations, and biological interpretation. Ann. Transl. Med. 6 (8), 157.

Robak, L.A., Jansen, I.E., van Rooij, J., Uitterlinden, A.G., Kraaij, R., Jankovic, J., International Parkinson's Disease Genomics Consortium (IPDGC), Heutink, P., Shulman, J.M., 2017. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain J. Neurol. 140 (12), 3191–3203.

Heinzel, S., Berg, D., Gasser, T., Chen, H., Yao, C., Ronald, B., Postuma, and MDS Task Force on the Definition of Parkinson's Disease, 2019. Update of the MDS research criteria for prodromal Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.27802. August.

Bandres-Ciga, Sara, Ahmed, Sarah, Sabir, Marya S., Blauwendraat, Cornelis, Adarmes-Gómez, Astrid D., Bernal-Bernal, Inmaculada, Bonilla-Toribio, Marta, et al., 2019b. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. https://doi.org/10.1101/609016.

Shi, C.-H., Luo, H.-Y., Yu, F., Li, Y.-S., Yu-Ming, X., 2018. LRP10 in α-Synucleinopathies. Lancet Neurol. 17 (12), 1034–1035.

Silveira, C.R.A., MacKinley, J., Coleman, K., Li, Z., Finger, E., Bartha, R., Morrow, S.A., et al., 2019. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. https://doi.org/10.1186/s12883-019-1252-3.

Simón-Sánchez, J., Schulte, C., Bras, J.M., Sharma, M., Raphael Gibbs, J., Berg, D., Paisan-Ruiz, C., et al., 2009. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41 (12), 1308–1312.

Singleton, A., Hardy, J., 2011. A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. Hum. Mol. Genet. 20 (R2), R158–R162.

Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., et al., 2003. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (5646), 841.

Sulzer, D., Alcalay, R.N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., et al., 2017. T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature. https://doi.org/10.1038/nature22815.

Tejera-Parrado, C., Jesús, S., López-Ruíz, A., Buiza-Rueda, D., Bonilla-Toribio, M., Bernal-Bernal, I., Periñán, M.T., Vargas-González, L., Gómez-Garre, P., Mir, P., 2018. TMEM230 in Parkinson's disease in a Southern Spanish population. PLoS One 13 (5), e0197271.

Tesson, C., Brefel-Courbon, C., Corvol, J.-C., Lesage, S., Brice, A., French Parkinson's Disease Genetics Study Group, 2018. LRP10 in α-Synucleinopathies. Lancet Neurol. 17 (12), 1034.

Trotta, L., Guella, I., Soldà, G., Sironi, F., Tesei, S., Canesi, M., Pezzoli, G., Goldwurm, S., Duga, S., Asselta, R., 2012. SNCA and MAPT genes: independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat. Disord. 18 (3), 257–262.

Van Den Eeden, S.K., 2003. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. https://doi.org/10.1093/aje/kwg068.

Vergouw, L.J.M., Ruitenberg, A., Wong, T.H., Melhem, S., Breedveld, G.J., Criscuolo, C., De Michele, G., et al., 2019. LRP10 variants in Parkinson's disease and dementia with Lewy bodies in the south-west of the Netherlands. Parkinsonism Relat. Disord. https://doi.org/10.1016/j.parkreldis.2019.05.037. May.

Wei, Q., Ou, R., Zhou, Q., Chen, Y., Cao, B., Gu, X., Zhao, B., Wu, Y., Song, W., Shang, H.-F., 2018. TMEM230 mutations are rare in Han Chinese patients with autosomal dominant Parkinson's disease. Mol. Neurobiol. 55 (4), 2851–2855.

Weissbrod, Omer, Hormozdiari, Farhad, Benner, Christian, Cui, Ran, Ulirsch, Jacob, Gazal, Steven, Schoech, Armin P., et al., 2019. Functionally-informed Fine-Mapping and Polygenic Localization of Complex Trait Heritability. *bioRxiv.* https://doi.org/10.1101/807792.

Williams, U., Bandmann, O., Walker, R., 2018. Parkinson's disease in Sub-Saharan Africa: a review of epidemiology, genetics and access to care. J. Mov. Disord. https://doi.org/10.14802/jmd.17028.

Wright Willis, A., Evanoff, B.A., Lian, M., Criswell, S.R., Racette, B.A., 2010. Geographic and ethnic variation in Parkinson disease: a population-based study of US medicare beneficiaries. Neuroepidemiology 34 (3), 143–151.

Wu, H., Zheng, X., Cen, Z., Xie, F., Chen, Y., Lu, X., Luo, W., 2017. Genetic analysis of the TMEM230 gene in chinese patients with familial Parkinson disease. Parkinsonism Relat. Disord. 36 (March), 105–106.

Yang, X., An, R., Xi, J., Zheng, J., Chen, Y., Huang, H., Tian, S., Zhao, Q., Ning, P., Xu, Y., 2017. Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson's disease. Movement Disorders 32 (5), 800–802.

Yang, J., Bakshi, A., Zhu, Z., Hemani, G., Vinkhuyzen, A.A.E., Lee, S.H., Robinson, M.R., et al., 2015. Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat. Genet. 47 (10), 1114–1120.

Young, A.I., 2019. Solving the missing heritability problem. PLoS Genet. 15 (6), e1008222.

Zabetian, C.P., Mata, I.F., Latin American Research Consortium on the Genetics of PD (LARGE-PD), 2017. LARGE-PD: examining the genetics of Parkinson's disease in Latin America. Movement Disorders 32 (9), 1330–1331.

Zarranz, J.J., Alegre, J., Gómez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., et al., 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2), 164–173.

Zhang, M., Hongbo, M., Shang, Z., Kang, K., Lv, H., Duan, L., Li, J., et al., 2017. Genome-wide pathway-based association analysis identifies risk pathways associated with Parkinson's disease. Neuroscience. https://doi.org/10.1016/j.neuroscience.2016.11.004.

Zhu, Z., Bakshi, A., Vinkhuyzen, A.A.E., Hemani, G., Lee, S.H., Nolte, I.M., van Vliet-Ostaptchouk, J.V., et al., 2015. Dominance genetic variation contributes little to the missing heritability for human complex traits. Am. J. Hum. Genet. 96 (3), 377–385.

Zuk, O., Hechter, E., Sunyaev, S.R., Lander, E.S., 2012. The mystery of missing heritability: genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. U. S. A. 109 (4), 1193–1198.

Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., et al., 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (9440), 1167–1169.

Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., et al., 2009. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41 (12), 1303.

Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., et al., 2013. G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann. Neurol. 73 (4), 459–471.

Kara, E., Xiromerisiou, G., Spanaki, C., Bozi, M., Koutsis, G., Panas, M., Dardiotis, E., et al., 2014. Assessment of Parkinson's disease risk loci in Greece. Neurobiol. Aging 35 (2), 442.e9–442.e16.

Funayama, M., Ohe, K., Amo, T., Furuya, N., Yamaguchi, J., Saiki, S., Li, Y., et al., 2015. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol. 14 (3), 274–282.

Masellis, M., Collinson, S., Freeman, N., Tampakeras, M., Levy, J., Tchelet, A., Eyal, E., et al., 2016. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. Brain. https://doi.org/10.1093/brain/aww109.

Buongarzone, G., Monfrini, E., Franco, G., Trezzi, I., Borellini, L., Frattini, E., Melzi, V., et al., 2017. Mutations in TMEM230 are rare in autosomal dominant Parkinson's disease. Parkinsonism Relat. Disord. 39 (June), 87–88.

Shi, C.-H., Li, F., Shi, M.-M., Yang, Z.-H., Mao, C.-Y., Zhang, S.-Y., Wang, H., et al., 2017. Genetic analysis of the TMEM230 gene in Chinese Han patients with Parkinson's disease. Sci. Rep. 7 (1), 1190.